Abstract
To estimate management costs of chemotherapy and allogeneic stem-cell transplant (allo-SCT) for adults with acute lymphoblastic leukemia (ALL) in France. Data were extracted from the French national hospitalization database (PMSI) for patients ≥18 years hospitalized in 2015 and/or 2016. Hospitalizations were selected using ICD-10 diagnosis code for ALL (C91.0). For chemotherapy, all patients with a chemotherapy stay in 2015-2016 were included. For allo-SCT, all patients with at least one allo-SCT stay in 2015-2016 after a previous chemotherapy stay in 2015 were included. For patients who underwent allo-SCT, graft versus host disease (GvHD) stays after the first allo-SCT stay were identified in 2015-2016. Stem cell donation stays were also identified in 2015-2016. All costs were valorized as production costs (ENCC 2014-2015), inflation adjusted (€2017), and studied considering the type of stays (day-care hospitalization vs inpatient) and age groups (<65 vs ≥65 years). Overall, 1,768 adult ALL patients were included, of which 1,285 (73%) were <65 years. Among these patients, a total of 15,494 hospital stays (day-care hospitalization: 59% vs inpatient: 41%) were retrieved. The average management cost of chemotherapy was €5,659/stay (day-care hospitalization: €403 vs inpatient: €13,146) and was higher for younger patients (<65 years: €5,981 vs ≥65 years: €4,516). Among the 275 patients who underwent allo-SCT, 257 (93%) were <65 years, 152 (55%) developed a GvHD. The average management cost of allo-SCT was €69,234/stay, the average management cost of GvHD was €17,042/stay, and the average cost of stem cell donation was €1,751/stay. In this study, management costs of chemotherapy and allo-SCT for adults with ALL in France were estimated from the PMSI database, in which type of ALL, stage of the disease and chemotherapy regimens are not available. This lack of clinical data could be addressed with experts.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.